Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients

Gene

Volumn 512, Issue 2, 2013, Pages 226-231

  Shi, Yunying ^a   Li, Yi ^a   Tang, Jiangtao ^a   Zhang, Junlong ^a   Zou, Yuangao ^a   Cai, Bei ^a   Wang, Lanlan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

CYP3A4; CYP3A5; Early renal injury; Liver transplantation; MDR 1; Polymorphism

Indexed keywords

ALPHA 1 MICROGLOBULIN; CREATININE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; IMMUNOGLOBULIN G; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; TRANSFERRIN;

ADULT; ARTICLE; CREATININE BLOOD LEVEL; DRUG DOSE COMPARISON; FEMALE; FOLLOW UP; GENE FREQUENCY; GENOTYPE; GRAFT RECIPIENT; HOMOZYGOTE; HUMAN; KIDNEY INJURY; LIVER GRAFT; LIVER GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; URINALYSIS;

ADULT; CYTOCHROME P-450 CYP3A; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84870347313     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.10.048     Document Type: Article

References (24)

1. Chew S.C. The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients. Cancer Chemother. Pharmacol. 2011, 67:1471-1478.
2. Cho J.H., et al. Impact of CYP3A and ABCB1 polymorphisms on tacrolimus dose-adjusted trough concentrations among renal transplant recipients in Korea. Transpl. Int. 2011, 24:284.
3. D'Amico G., Bazzi C. Urinary protein and enzyme excretion as markers of tubular damage. Curr. Opin. Nephrol. Hypertens. 2003, 12:639-643.
4. Elens L., et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin. Chem. 2011, 57:1574-1583.
5. Finn W.F. FK506 nephrotoxicity. Ren. Fail. 1999, 21:319-329.
6. Franchini I., Alinovi R., Bergamaschi E., Mutti A. Contribution of studies on renal effects of heavy metals and selected organic compounds to our understanding of the progression of chronic nephropathies towards renal failure. Acta Biomed. 2005, 76(Suppl. 2):58-67.
7. Fredericks S., et al. Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements. Transplantation 2006, 82:705-708.
8. Haufroid V., et al. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. Am. J. Transplant. 2006, 6:2706-2713.
9. Hebert M.F., et al. Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics 2003, 13:661-674.
10. Jun K.R., et al. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea. Transplantation 2009, 87:1225-1231.
11. Jung K. Urinary enzymes and low molecular weight proteins as markers of tubular dysfunction. Kidney Int. Suppl. 1994, 47:S29-S33.
12. Jung K., Pergande M., Graubaum H.J., Fels L.M., Endl U., Stolte H. Urinary proteins and enzymes as early indicators of renal dysfunction in chronic exposure to cadmium. Clin. Chem. 1993, 39:757-765.
13. Kubal C., et al. Chronic kidney disease after nonrenal solid organ transplantation: a histological assessment and utility of chronic allograft damage index scoring. Transplantation 2012, 93:406-411.
14. Li J., et al. Microproteinuria for detecting calcineurin inhibitor-related nephrotoxicity after liver transplantation. World J. Gastroenterol. 2009, 15:2913-2917.
15. Mogensen C.E. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N. Engl. J. Med. 1984, 310:356-360.
16. Picard N., Marquet P. The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation. Expert Opin. Drug Metab. Toxicol. 2011, 7:731-743.
17. Renders L., et al. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin. Pharmacol. Ther. 2007, 81:228-234.
18. Schaub S., et al. Detection of subclinical tubular injury after renal transplantation: comparison of urine protein analysis with allograft histopathology. Transplantation 2007, 84:104-112.
19. Singh R., Srivastava A., Kapoor R., Mittal R.D. Do drug transporter (ABCB1) SNPs influence cyclosporine and tacrolimus dose requirements and renal allograft outcome in the posttransplantation period?. J. Clin. Pharmacol. 2011, 51:603-615.
20. Staatz C.E., Goodman L.K., Tett S.E. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II. Clin. Pharmacokinet. 2010, 49:207-221.
21. Uchida J., et al. Renal endothelin in FK506-induced nephrotoxicity in spontaneously hypertensive rats. Jpn. J. Pharmacol. 1998, 76:39-49.
22. Velidedeoglu E., et al. Early kidney dysfunction post liver transplantation predicts late chronic kidney disease. Transplantation 2004, 77:553-556.
23. Wang D., Guo Y., Wrighton S.A., Cooke G.E., Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 2011, 11:274-286.
24. Wu P., Ni X., Wang M., Xu X., Luo G., Jiang Y. Polymorphisms in CYP3A5*3 and MDR1, and haplotype modulate response to plasma levels of tacrolimus in Chinese renal transplant patients. Ann. Transplant. 2011, 16:54-60.